



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

12 March 2026
EMA/354254/2025
Management Board

Union Product Database (UPD) Access Policy Veterinary Medicinal Products

POLICY/no 0082
Status: Public
Effective date: 1 April 2026
Review date: 1 April 2029
Supersedes: EMA/259966/2024



Table of contents

1. Introduction and purpose	3
2. Scope	3
3. Policy statement	4
3.1. Union Product Database	4
3.2. Access to Union Product Database	5
3.2.1. Stakeholder groups.....	5
3.2.2. General principles.....	6
3.2.3. Personal Data Protection	6
3.2.4. Methods of providing access to veterinary medicinal product information held in UPD	7
3.2.5. Detailed description of access to veterinary medicinal product data held in UPD, by Stakeholder	9
4. Related documents	11
5. Changes since last revision	11
Annex A – Product data elements accessible by stakeholder group	12

1. Introduction and purpose

The European Medicines Agency (hereafter referred to as “the Agency”) and the Member States’ competent authorities collectively comprise the European Union (EU) regulatory network. The network’s responsibilities are the protection and promotion of public and animal health and the environment through the evaluation and supervision of medicines.

Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC (‘the VMP Regulation’), was adopted on 11 December 2018, entered into force on 28 January 2019 and became applicable from 28 January 2022, following a 3-year implementation period. The VMP Regulation contains new measures for increasing the availability and safety of veterinary medicines, enhances EU action against antimicrobial resistance and will modernise the existing rules on the authorisation and use of veterinary medicines in the EU.

The VMP Regulation mandates that the Agency establishes and, in collaboration with the Member States, maintains, a Union database on veterinary medicinal products (UPD), containing information on veterinary medicinal products authorised within the Union, homeopathic veterinary medicinal products registered within the Union, veterinary medicinal products exempted in a Member State from the marketing authorisation requirements, and parallel traded products. This database shall also register the annual volume of sales, information on the availability for each veterinary medicinal product and variations not requiring assessment for authorised veterinary medicinal products.

Commission Implementing Regulation (EU) 2021/16 of 8 January 2021 laying down the necessary measures and practical arrangements for the Union database on veterinary medicinal products details the specifications to implement in order to fulfil the requirements of the VMP Regulation. In this context, it was mandated that a detailed access policy be drawn up and applied by the Agency, in collaboration with the competent authorities and the European Commission, and in consultation with marketing authorisation holders, before the UPD became operational. The policy enables actors to perform their obligations as provided for in the VMP Regulation, while protecting commercially confidential information and personal data. It therefore provides different levels of access to the UPD processes. The first version of the policy (EMA/198149/2020) was adopted on 25 January 2021.

2. Scope

This Access Policy defines the overall principles for providing access to veterinary medicinal product information held in the UPD in line with the EU legislative framework, considering that the interest in and the use of the data may vary between stakeholders.

The policy provides transparency and visibility of information on veterinary medicinal products while protecting commercially confidential information in accordance with Regulation (EC) No 1049/2001. Requirements to protect personal data based on Regulation (EU) 2016/679 and Regulation (EU) 2018/1725 are reflected in the policy accordingly.

‘Veterinary medicinal products’ in this policy include

- authorised veterinary medicinal products;
- registered homeopathic veterinary medicinal products;
- veterinary medicinal products exempted in a Member State from the marketing authorisation requirements under Article 5(6); and
- parallel traded products.

The VMP Regulation defines the level of UPD access as follows (Article 56):

1. *The competent authorities, the Agency and the Commission shall have full access to the information in the product database.*
2. *Marketing authorisation holders¹ shall have full access to the information in the product database as regards their marketing authorisations.*
3. *The general public shall have access to information in the product database, without the possibility to change the information therein, as regards the list of the veterinary medicinal products, the summary of product characteristics, package leaflets and, after the deletion of any commercially confidential information by the competent authority, the assessment reports.*

Furthermore, specific access arrangements are required for the United Kingdom acting in respect of Northern Ireland to comply with its obligations under the Windsor Framework. The description of individual scenarios and veterinary medicinal products are further outlined in Annex A.

3. Policy statement

This Access Policy has been developed with the goal of facilitating the maintenance of and accessibility to information on veterinary medicinal products in the EU, within the overall aim of promoting and protecting animal and public health and the environment.

Furthermore, this Access Policy aims to meet the EU principles of transparency and openness while ensuring compliance with EU personal data protection legislation. The following objectives should be met, by providing proactive access to product information on veterinary medicinal products:

1. Increasing availability of and access to information on veterinary medicinal products authorised to treat and prevent animal diseases in the EU for veterinarians, farmers and pet owners and any other interested parties;
2. Supporting the functioning of the internal EU market for veterinary medicinal products;
3. Improving transparency of veterinary medicinal products used in the EU;
4. Strengthening the decision making for the European Commission, competent authorities and marketing authorisation holders by providing access to data analytics and reports;
5. Simplifying the regulatory environment and reducing the administrative burden by giving marketing authorisation holders and competent authorities access to the functionalities of the variations without assessment module of the UPD.

3.1. Union Product Database

The UPD comprises a range of functions required for the administration and quality management of information related to veterinary medicinal products and its secure electronic transmission. Additionally, the UPD offers a specific mechanism for handling a change to the data that occurs when such changes are based on a variation that does not require assessment. A set of components has been designed, enhanced or reutilised to support such functionalities:

¹ 'Marketing authorisation holder' is defined in this policy to include: holder of the marketing authorisation for a veterinary medicinal product, of the registration for a homeopathic veterinary medicinal product or of the exemption for products allowed for use in accordance with Article 5(6) of Regulation (EU) 2019/6

- **Access management component** which manages the control of access to data or functionalities and ensures that all stakeholders have the appropriate access to the resources provided by the UPD and the proper permissions to perform actions in the UPD.
- **Data and document submission component** which manages the requests for submission to the UPD of data and documents relating to new veterinary medicinal products in order to create a new dataset, variations and other post-authorisation changes to the datasets already existing in the UPD for veterinary medicinal products.
- **Application programming interface (API)²** for the exchange of data and documents with the systems used by marketing authorisation holders, competent authorities, the Agency, the European Commission and other general public registered users.
- **UPD portal** which, with the use of data publishing, data searching, viewing and exporting, as well as data analytics, presents information to users and makes certain features available to them in accordance with their access rights (objective 4).
- **Data and document repository component** which manages all data and documents that enter into the UPD.
- **Component to manage variations that do not require assessment** which allows the marketing authorisation holder to record a variation that does not require assessment and allows the relevant competent authority or the European Commission, as applicable, to be notified and to approve or reject such variations prior to the update in the UPD, to update the dataset accordingly and to store and update related documentation (objective 5).
- **General public module** which is part of the UPD portal and allows the general public to search and view all publicly available data and documents on veterinary medicinal products referred to in Article 56 of the VMP Regulation (objectives 1, 2 and 3).

Different levels of access to these components must be defined and implemented to ensure that the different stakeholders interacting with the UPD can access the information necessary to fulfil their responsibilities as outlined in the VMP Regulation and related Implementing Acts or enjoy their right to access information.

3.2. Access to Union Product Database

3.2.1. Stakeholder groups

The stakeholders being granted access to UPD data can be grouped as follows:

- **The European Commission, the competent authorities³, including, as necessary, the United Kingdom acting in respect of Northern Ireland, and the Agency** including contractors and external service providers working for them on UPD related subjects;
- **Marketing authorisation holders**, including contractors and external service providers working for them on UPD related subjects;
- **General Public:** persons or organisations, other than the two groups referred to above, e.g. veterinary health care professionals and other interested persons.

² Access to and use of the API is subject to prior acceptance by the user of the [EMA – API General Terms of Service – Terms of Use](#)

³ Competent authorities as defined in Article 4(23) of Regulation (EU) 2019/6

3.2.2. General principles

Veterinary medicinal products are recorded in the UPD as derived from legal obligations placed on competent authorities and marketing authorisation holders.

The VMP Regulation gives the widest possible access to veterinary medicinal product data and to the related documents while protecting certain public and private interests, such as personal data and commercially confidential information in accordance with Regulation (EC) No 1049/2001.

The data elements for veterinary medicinal product data stored in the UPD are defined in [Commission Implementing Regulation \(EU\) 2021/16](#) of 8 January 2021 laying down the necessary measures and practical arrangements for the Union database on veterinary medicinal products ('the Implementing Regulation') and further detailed in the [EU Implementation Guide on veterinary medicines product data in the Union Product Database](#) ('the EU Vet Implementation Guide').

Access is defined based on the stakeholder's interests and needs as well as the requirement to comply with EU personal data protection legislation (Regulation (EU) 2016/679 or General Data Protection Regulation (GDPR)). The protection of personal data is a fundamental right of Europeans. The access is further defined at different levels considering that due to the nature of the information not all data elements can be disclosed to avoid identification of data subjects or dissemination of commercially confidential information.

Annex A lists all UPD veterinary medicinal product data elements and outlines which can be accessed by the different stakeholder groups, based on the access levels described in Table 1.

Table 1. Description of access levels

Access Level	Description
Level 1	Public subset of veterinary medicinal product data elements with focus on the General Public user group.
Level 2	Extended subset of veterinary medicinal product data elements with focus on the marketing authorisation holder user group to fulfil their legal responsibilities for their own products, which have been recorded in the database by the authorities.
Level 3A	All veterinary medicinal product data elements without restrictions with focus on the competent authorities (excluding the United Kingdom acting in respect of Northern Ireland), the European Commission and the Agency, taking into account their roles and responsibilities under the VMP Regulation.
Level 3B	Relevant subset of veterinary medicinal product data elements to enable the partial access granted on the basis of Article 13(5) of the Windsor Framework to the United Kingdom acting in respect of Northern Ireland to comply with its obligations under the Windsor Framework.

3.2.3. Personal Data Protection

The Agency, the competent authorities, including the United Kingdom acting in respect of Northern Ireland, and marketing authorisation holders are all responsible for ensuring confidentiality of veterinary medicinal product data and protecting personal data by implementing appropriate technical and organisational measures to protect information and personal data processed against unauthorised or unlawful access, disclosure, dissemination, alteration, or destruction or accidental loss in accordance with the applicable law on personal data protection.

Personal data shall mean any information relating to an identified or identifiable natural person ('data subject'); an identifiable natural person is one who can be identified, directly or indirectly, in particular by reference to an identifier such as a name, an identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that natural person; (Article 3(1) of Regulation (EU) 2018/1725).

For the Agency, the provisions set out in Regulation (EU) 2018/1725 apply; for competent authorities and marketing authorisation holders, the rules set out in Regulation (EU) 2016/679 (GDPR) apply.

3.2.4. Methods of providing access to veterinary medicinal product information held in UPD

Access to UPD data is provided through query and data retrieval functions based on the UPD system components described in section 3.1. Table 2 provides an overview of the UPD system components applied to provide access to UPD data for each stakeholder group and outlines the overall format of the data outputs.

Table 2. UPD system components with UPD product data outputs by stakeholder group

UPD System Component	Data Inputs	Data Outputs
Stakeholder: the European Commission, the competent authorities, including, as necessary, the United Kingdom acting in respect of Northern Ireland, and the Agency		
Data and document submission portal	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
Application programming interface	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
UPD portal	N/A	Web page(s) in HTML format; showing all product data and providing search functions
Management of variations not requiring assessment component	Approvals/Rejections	Web pages in HTML format
Data and document repository component	Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)

UPD System Component	Data Inputs	Data Outputs
Stakeholder: Marketing authorisation holders		
Data and document submission portal	Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
Application programming interface	Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
UPD portal	N/A	Web page(s) in HTML format; showing only data in accordance with their access rights and providing search functions
Management of variations not requiring assessment component	Structured electronic content	Web pages in HTML format
Data and document repository component	Role Based Access Control (RBAC) will determine which structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)
Stakeholder: General public		
UPD portal	N/A	Web page(s) in HTML format; showing only the subset of data that is available to the public and providing search functions
Application programming interface	N/A	Structured electronic content (XML and JSON formats) and unstructured content (e.g. PDF)

3.2.5. Detailed description of access to veterinary medicinal product data held in UPD, by Stakeholder

3.2.5.1. The European Commission, competent authorities and the Agency

3.2.5.1.1. Veterinary medicinal products in UPD

In accordance with the VMP Regulation, the competent authorities, the Agency and the European Commission shall have full access to the information in the UPD.

The United Kingdom acting in respect of Northern Ireland shall have the partial access to the information in the UPD granted on the basis of Article 13(5) of the Windsor Framework.

Table 3. Access to UPD data by the competent authorities, the Agency and the European Commission

Stakeholder	Access Level	Access Type
Level 3A: <ul style="list-style-type: none">Competent authorities (excluding the United Kingdom acting in respect of Northern Ireland)AgencyEuropean CommissionContractors and external service providers working for the above authorities on the UPD subject	<ul style="list-style-type: none">UPD Level 3A:<ul style="list-style-type: none">All data elements for veterinary medicinal products reported to UPD.	Authorised personnel only
Level 3B: <ul style="list-style-type: none">United Kingdom acting in respect of Northern IrelandContractors and external service providers working for the United Kingdom acting in respect of Northern Ireland on the UPD subject	<ul style="list-style-type: none">UPD Level 3B:<ul style="list-style-type: none">As required for the partial access granted on the basis of Article 13(5) of the Windsor Framework to the United Kingdom acting in respect of Northern Ireland to comply with its obligations under the Windsor Framework.	Authorised personnel only

3.2.5.1.2. Methods of access

A description of how access is provided to these stakeholders including the main data outputs is given in Section 3.2.4.

3.2.5.1.3. Access authorisation

Access is granted to authorised personnel of the European Commission, the Agency and the competent authorities, including, as necessary, the United Kingdom acting in respect of Northern Ireland. The identification of 'authorised personnel' is detailed in the UPD registration process described in the registration guide⁴. Contractors and external service providers are also considered "authorised personnel" and their access rights are administrated by the relevant organisation on whose behalf access is granted.

3.2.5.1.4. Personal data protection requirements

Data access and provision is based on a defined veterinary medicinal product data set (Level 3A and Level 3B) in compliance with the VMP Regulation. A Data Protection Notice is included on the UPD

⁴ [UPD registration guide for veterinary medicinal products \(europa.eu\)](https://european-commission.europa.eu/UPD-registration-guide)

Portal, explaining in detail how personal data are processed. The Agency is also operating a procedure for access and rectification in line with the aforementioned Regulation.

3.2.5.2. Marketing authorisation holders

3.2.5.2.1. Veterinary medicinal products in the UPD

In accordance with the VMP Regulation, the marketing authorisation holders shall have full access to the information in the UPD as regards their products.

Table 4. Access to UPD data by marketing authorisation holders

Stakeholder	Access Level	Access Type
<ul style="list-style-type: none"> Marketing Authorisation Holders Contractors and external service providers working for the above companies on the UPD subject 	<ul style="list-style-type: none"> UPD Level 2: <ul style="list-style-type: none"> Subset of data elements for veterinary medicinal products reported to UPD (for details refer to Annex A) 	Authorised Personnel only

3.2.5.2.2. Methods of access

A description of how access is provided to these stakeholders including the main data outputs is given in Section 3.2.4.

3.2.5.2.3. Access authorisation

Access is granted to authorised personnel of the marketing authorisation holders. The identification of 'authorised personnel' is detailed in the UPD registration process described in the registration guide⁴. Contractors and external service providers are also considered "authorised personnel" and their access rights are administrated by the relevant organisation on whose behalf access is granted.

3.2.5.2.4. Personal data protection requirements

Data access and provision is based on a defined veterinary medicinal product data set (Level 2) in compliance with the VMP Regulation. A Data Protection Notice is included on the UPD Portal, explaining in detail how personal data are processed. The Agency is also operating a procedure for access and rectification in line with the aforementioned Regulation.

3.2.5.3. General public

3.2.5.3.1. Report of veterinary medicinal product

In accordance with the VMP Regulation, the general public shall have access to information in the UPD, without the possibility to change the information therein, as regards the list of the veterinary medicinal products, the summary of product characteristics, package leaflets and, after the deletion of any commercially confidential information by the competent authority, assessment reports.

Table 5. Access to UPD data by general public

Stakeholder	Access Level	Access Type
<ul style="list-style-type: none"> General public 	<ul style="list-style-type: none"> UPD Level 1: 	Not required/controlled

	<ul style="list-style-type: none"> - Subset of data elements for veterinary medicinal products reported to UPD (for details refer to Annex A) 	
--	--	--

3.2.5.3.2. Methods of access

A description of how access is provided to these stakeholders including the main data outputs is given in Section 3.2.4.

3.2.5.3.3. Access authorisation

No registration, authorisation or authentication shall be required to access the public interface of the UPD (Veterinary Medicines information website). Registration, authentication and authorisation will be required to access publicly available data via the Public API.

3.2.5.3.4. Personal data protection requirements

Data access and provision is based on a defined veterinary medicinal product data set (Level 1) in compliance with the VMP Regulation. A Data Protection Notice is included on the UPD Portal, explaining in detail how personal data are processed. The Agency is also operating a procedure for access and rectification in line with the aforementioned Regulation.

4. Related documents

[Joint Controllership Arrangement with regard to the Union Product Database \(UPD\)](#)

[European Medicines Agency's Data Protection Notice for the Union Product Database \(UPD\)](#)

5. Changes since last revision

The main changes in this version of the policy are the establishment of a new access level (Level 3B) applicable to the United Kingdom acting in respect of Northern Ireland in line with the partial access granted on the basis of Article 13(5) of the Windsor Framework⁵.

Other minor changes include the addition of the 'package identifier(s)' in the Annex A for all stakeholders, and editorial amendments.

Amsterdam,

[Signature on file]

Emer Cooke
Executive Director

⁵ The Windsor Framework is the new way in which the Protocol on Ireland/Northern Ireland is referred to in accordance with Joint Declaration No 1/2023 of the Union and the United Kingdom in the Joint Committee established by the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community of 24 March 2023 (OJ EU L 102, 17.4.2023, p. 87).

Annex A – Product data elements accessible by stakeholder group

RCUD = Read, Create, Update, Delete

UK(NI) = United Kingdom acting in respect of Northern Ireland

Y/N = yes, no

The numbering reflects the field numbering in Annex II and III of the Implementing Regulation.

UPD fields ⁶	Level 3A												Level 3B ⁷				Level 2				Level 1			
	European Commission				Competent Authorities (excluding UK(NI))				Agency				UK(NI)				Marketing Authorisation Holders				General Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ^(a)	D	R	C	U	D
1. For all veterinary medicinal products																								
1.1 Product Domain	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
1.2 Product Type	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
1.3 Product Name	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
1.4 Active Substance(s)	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
1.5 Strength/Composition	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
1.6 Manufacturing Sites	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y ^(e)	N	N	N	Y ^(b)	N	N	N
(.) Operation type (for manufacturing site)	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y ^(e)	N	N	N	Y ^(b)	N	N	N
1.7 Documents (SPC, PL, labelling, PuAR) ⁸	Y	N	N	N	Y	Y ^(c)	Y ^(c)	N	Y	Y	Y	N	Y	Y ^(c)	Y ^(c)	N	Y	N	N	N	Y	N	N	N
2. Only for authorised veterinary medicinal products																								
2.1 Dates of Placing on the Market	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y ^(d)	N	N	Y	N	N	N

⁶ The available information in the data fields depends on the authorisation procedure type of veterinary medicinal product (authorised, registered homeopathic, Art. 5(6) exemption or parallel traded product).

⁷ As required for the partial access granted on the basis of Article 13(5) of the Windsor Framework to the United Kingdom acting in respect of Northern Ireland to comply with its obligations under the Windsor Framework.

⁸ The document types are: Summary of Product Characteristics, package leaflet including labelling, public assessment report.

UPD fields ⁶	Level 3A												Level 3B ⁷				Level 2				Level 1			
	European Commission				Competent Authorities (excluding UK(NI))				Agency				UK(NI)				Marketing Authorisation Holders				General Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ^(a)	D	R	C	U	D
2.2 Annual Volume of Sales ⁹	Y	N	N	N	Y	N	N	N	Y	N	N	N	N	N	N	N	Y ^(d)	Y ^(d)	Y ^(d)	N	N	N	N	N
2.3 Date of Availability Status	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y ^(d)	Y ^(d)	N	Y	N	N	N
2.4 Availability Status	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y ^(d)	Y ^(d)	N	Y	N	N	N
Product Grouping ¹⁰	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Y ^(d)	Y ^(d)	Y ^(d)	Y ^(d)	N	N	N	N
Third Country Product Name ¹⁰	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Y ^(d)	Y ^(d)	Y ^(d)	Y ^(d)	N	N	N	N
3. For all veterinary medicinal products																								
3.1 Permanent Identifier	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N
3.2 Product Identifier	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N
3.3 Product Owner	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.4 Authorisation Status	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	Y ^(d)	N	Y	N	N	N
3.5 Date of Authorisation Status Change	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	Y ^(d)	N	Y	N	N	N
3.6 Route of Administration	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.7 Pharmaceutical Form	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.8 Target Species	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.9 ATCvet Code	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.10 Withdrawal Period	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.11 PSMF Number	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.12 PSMF Location	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
3.13 QPPV Name	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y ^(d)	N	N	N	N	N	N	N
3.14 QPPV Location	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y ^(d)	N	N	N	N	N	N	N
QPPV Email ¹⁰	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y ^(d)	N	N	N	N	N	N	N
3.15 Package Description	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
(.) Package Identifier(s)	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N
3.16 Legal Status for Supply	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N

⁹ Information on Annual Volume of Sales refer to the following fields: volume of sales, reporting period (year-month), dose factor, species, estimated distribution across target species and comment which relates to any additional information provided by the Marketing Authorisation Holder.

¹⁰ Attribute introduced in UPD to support pharmacovigilance regulatory processes and other procedural aspects.

UPD fields ⁶	Level 3A												Level 3B ⁷				Level 2				Level 1			
	European Commission				Competent Authorities (excluding UK(NI))				Agency				UK(NI)				Marketing Authorisation Holders				General Public			
	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U	D	R	C	U ^(a)	D	R	C	U	D
4. Procedural information for initial authorisation																								
4.1 Authorisation Procedure Type	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
4.2 Authorisation Procedure Number	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
4.3 Marketing Authorisation Date	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
4.4 Authorisation Country	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
4.5 Reference Member State	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N	Y	N	N	N
4.6 Member States Concerned	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N	Y	N	N	N
4.7 Legal Basis	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	N	Y	N	N	N
4.8 Authorisation Number	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
4.9 Reference Product Identifier	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
4.10 Source Product Identifier	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
(.) Responsible Authority (Organisation)	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
5. Procedural information for post-authorisation changes																								
5.1 Submission Identifier	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ^(d)	N	N	N	N	N	N	N
5.2 Authorisation Procedure Number	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y ^(d)	Y ^(d)	N	N	N	N	N	N
5.3 Responsible Authority	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ^(d)	Y ^(d)	N	N	N	N	N	N
5.4 Variation Classification Code	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ^(d)	Y ^(d)	N	N	N	N	N	N
5.5 Submission Comment	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ^(d)	Y ^(d)	N	N	N	N	N	N
5.6 Date of Implementation	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	Y ^(d)	N	N	N	N	N	N
5.7 Date of Submission	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y	N	N	N	Y ^(d)	N	N	N	N	N	N	N
5.8 Decision	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y ^(d)	N	N	N	N	N	N	N
5.9 Date of Decision	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y ^(d)	N	N	N	N	N	N	N
5.10 Author of Decision	Y	N	N	N	Y	Y	N	N	Y	Y	N	N	Y	Y	N	N	Y ^(d)	N	N	N	N	N	N	N
6.1 Source Wholesale Distributor	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N
6.2 Destination Wholesale Distributor	Y	N	N	N	Y	Y	Y	N	Y	Y	Y	N	Y	Y	Y	N	Y	N	N	N	Y	N	N	N

- (a) Marketing authorisation holders can request the update of some of these fields, by the relevant Competent Authorities, via variation that does not require assessment or variation requiring assessment
- (b) Only visible for batch release manufacturing sites
- (c) For mutual recognition (MRP), decentralised (DCP) and subsequent recognition procedures, the reference member state (RMS) is responsible for creating or updating the English version of the documents
- (d) Only visible to the marketing authorisation holder that owns that veterinary medicinal product
- (e) Only visible to the marketing authorisation holder that owns that veterinary medicinal product, except for batch release manufacturing sites